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Abstract
Drug-induced interstitial lung disease (ILD), particularly pulmonary fibrosis, is of serious clinical concern. Gefitinib, a tyrosine
kinase inhibitor of the epidermal growth factor receptor (EGFR), is beneficial as a drug for treating non-small cell lung
cancer; however, this drug induces ILD and the molecular mechanisms underpinning this condition remain unclear. We
recently reported that expression of heat shock protein 70 (HSP70) protects against bleomycin-induced pulmonary fibrosis,
an animal model of pulmonary fibrosis. In this study, we have examined the effects of drugs known to induce ILD clinically
on the expression of HSP70 in cultured lung epithelial cells and have found that gefitinib has a suppressive effect. Results of
a luciferase reporter assay, pulse-labelling analysis of protein and experiments using an inhibitor of translation or
transcription suggest that gefitinib suppresses the expression of HSP70 at the level of translation. Furthermore, the results
of experiments with siRNA for Dicer1, an enzyme responsible for synthesis of microRNA, and real-time RT-PCR analysis
suggest that some microRNAs are involved in the gefitinib-induced translational inhibition of HSP70. Mutations in the EGFR
affect the concentration of gefitinib required for suppressing the expression of HSP70. These results suggest that gefitinib
suppresses the translation of HSP70 through an EGFR- and microRNA-mediated mechanism. In vivo, while oral
administration of gefitinib suppressed the pulmonary expression of HSP70 and exacerbated bleomycin-induced pulmonary
fibrosis in wild-type mice, these effects were not as distinct in transgenic mice expressing HSP70. Furthermore, oral co-
administration of geranylgeranylacetone (GGA), an inducer of HSP70, suppressed gefitinib-induced exacerbation of
bleomycin-induced pulmonary fibrosis. Taken together, these findings suggest that gefitinib-induced exacerbation of
bleomycin-induced pulmonary fibrosis is mediated by suppression of pulmonary expression of HSP70 and that an inducer
of HSP70 expression, such as GGA, may be therapeutically beneficial for the treatment of gefitinib-induced pulmonary
fibrosis.
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Introduction
Interstitial lung disease (ILD), in particular interstitial pneumo-
nia associated with pulmonary fibrosis, is a devastating chronic
lung condition with poor prognosis. Pulmonary fibrosis progresses
insidiously, with acute exacerbation of interstitial pneumonia
being a highly lethal clinical event [1], [2]. Although most cases of
pulmonary fibrosis are idiopathic, some are due to drug side effects
(drug-induced pulmonary fibrosis). For example, the anti-tumour
drugs gefitinib and imatinib, as well as anti-rheumatoid arthritis
drugs such as leflunomide, are known to induce ILD (pulmonary
fibrosis). This is cause for serious clinical concern, as it restricts the
therapeutic use of these drugs [3], [4], [5]. Unfortunately, the
etiology of drug-induced ILD (pulmonary fibrosis) is not yet
understood and, as a result, an appropriate animal model has not
yet been established. Understanding the mechanism governing
drug-induced ILD (pulmonary fibrosis) and developing a viable
animal model are therefore important to establish not only a
clinical protocol for its treatment but also an assay system that will
facilitate screening in order to eliminate candidate drugs with the
potential to produce this type of side effect. Bleomycin-induced
pulmonary fibrosis in animals mimics some characteristics of
human pulmonary fibrosis [6]. We recently reported that
leflunomide exacerbates bleomycin-induced pulmonary fibrosis,
proposed that this model is a suitable animal model for drug-
induced ILD, and suggested that this exacerbation is mediated by
epithelial-mesenchymal transition (EMT) of lung epithelial cells
[7]. However, the molecular mechanisms underpinning ILD
(pulmonary fibrosis) induced by drugs other than leflunomide
remain unclear.
Pulmonary fibrosis is induced by repeated epithelial cell damage
by reactive oxygen species (ROS) and other stressors and
abnormal wound repair and remodelling, resulting in abnormal
deposition of extracellular matrix (ECM) proteins, such as
collagen. In addition to the increase in transforming growth factor
(TGF)-b1 [8], an increase in the level of lung myofibroblasts has
been suggested to play an important role in pulmonary fibrosis [9].
It was previously believed that the sole origin of myofibroblasts is
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27296peribronchiolar and perivascular fibroblasts that transdifferentiate
into myofibroblasts [10]. However, recently, it was revealed that
some of the lung myofibroblasts in pulmonary fibrosis patients
originate from lung epithelial cells via EMT [11], [12], [13], [14].
Gefitinib, a tyrosine kinase inhibitor of the epidermal growth
factor receptor (EGFR), is a new molecular target agent for the
treatment of patients with advanced non-small cell lung cancer
who fail to respond to chemotherapy [15]. Furthermore, recent
clinical studies have shown that this drug is particularly effective
for patients with EGFR mutations, which causes constitutive
activation of EGFR-dependent intracellular signal transduction
[16], [17]. Although gefitinib has been recognised as relatively safe
based on data from clinical trials, post-marketing surveillance of
patients prescribed with gefitinib in Japan has revealed that 6.8%
of patients developed interstitial pneumonia and that, of these,
40% of the patients died [4], [18], [19]. The incidence of gefitinib-
induced ILD and its mortality rate are higher in Japan than in
Western countries [20], [21]. However, the mechanism governing
gefitinib-induced ILD (pulmonary fibrosis) and the reason for this
ethnic difference is unknown. Furthermore, contradictory results
have been reported regarding the effect of gefitinib on bleomycin-
induced pulmonary fibrosis in animals (prevention and exacerba-
tion) [22], [23] and the mechanisms governing these phenomena
are unknown.
Different stressors induce cells to express heat shock proteins
(HSPs) through transcriptional regulation mediated by a tran-
scription factor, heat shock factor 1 (HSF1), and a cis-element
located in the hsp gene promoter, heat shock element (HSE) [24].
HSPs, especially HSP70, expressed in cultured cells protect these
cells against a range of stressors, including ROS, by refolding or
degrading denatured proteins produced by the stressors (HSPs
function as molecular chaperones) [24], [25]. Interestingly,
geranylgeranylacetone (GGA), a leading anti-ulcer drug on the
Japanese market, has been reported to be a non-toxic HSP-
inducer [26], [27]. In addition to the cytoprotective effects of
HSP70, its anti-inflammatory effects have been identified recently
[28]. We have shown that through the cytoprotective, anti-
inflammatory and molecular chaperone activities, both genetic
and pharmacologic (by GGA) induction of expression of HSP70 is
protective in animal models of various diseases, such as gastric and
small intestinal lesions, inflammatory bowel diseases, ultraviolet
light-induced skin damage and Alzheimer’s disease [29], [30],
[31], [32], [33], [34]. Furthermore, we recently reported that
bleomycin-induced lung injury, inflammation, fibrosis and dys-
function are suppressed in transgenic mice expressing HSP70 or in
GGA-administered wild-type mice. We also suggested that HSP70
plays this protective role through cytoprotective and inflammatory
effects and by inhibiting the production of TGF-b1 and TGF-b1-
dependent EMT of lung epithelial cells [35].
As a mechanism for the regulation of gene expression,
microRNAs (miRNAs) have been paid much attention recently.
miRNAs are short non-coding single-stranded RNA species which
bind to complementary regions of the 3’ untranslated regions
(UTRs) of mRNA resulting in repression of translation and/or
stimulation of degradation of mRNA. Primary miRNA transcripts
are first processed in the nucleus to produce hairpin RNAs (pre-
miRNAs), which are then exported into the cytoplasm, where
Dicer1 cuts the hairpin to produce miRNAs [36]. Aberrant
expression of miRNAs is associated with pathologic conditions,
such as cancer, diabetes and fibrosis [36,37].
In this study, we examined the effect on the expression of
HSP70 of drugs known to induce ILD clinically in cultured lung
epithelial cells, and found that gefitinib suppresses the expression
of HSP70. The results suggest that gefitinib regulates expression of
HSP70 at the level of translation through an EGFR- and miRNA-
mediated mechanism. We also found that oral administration of
gefitinib suppresses pulmonary expression of HSP70 and suggested
that this suppression is involved in gefitinib-induced exacerbation
of bleomycin-induced pulmonary fibrosis. These results suggest
that HSP70 plays an important role in gefitinib-induced ILD
(pulmonary fibrosis) and that examination of the effect of drugs on
HSP70-expression in vitro is useful as a screening system in order to
eliminate candidate drugs with the potential to induce ILD.
Materials and Methods
Ethics Statement
The experiments and procedures described here were carried
out in accordance with the Guide for the Care and Use of
Laboratory Animals as adopted and promulgated by the National
Institutes of Health, and were approved by the Animal Care
Committee of Kumamoto University. Permit numbers or approval
ID for this study is C-20–166-R1.
Chemicals and animals
Paraformaldehyde, fetal bovine serum (FBS), 4-(dimethyla-
mino)-benzaldehyde (DMBA), chloramine T, cycloheximide,
SP600125, Orange G, RPMI1640 and DMEM were obtained
from Sigma (St. Louis, MO). Bleomycin was purchased from
Nippon Kayaku (Tokyo, Japan). An RNeasy kit, miScript miRNA
Mimic and HiPerFect were obtained from Qiagen (Valencia, CA),
the PrimeScriptH 1st strand cDNA synthesis kit was from
TAKARA Bio (Ohtsu, Japan), and the iQ SYBR Green Supermix
was from Bio-Rad (Hercules, CA). The mirVana miRNA isolation
kit and pMIR-REPORT System were purchased from Applied
Biosystems (Carlsbad, CA). Antibodies against actin and HSP70
were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA) and BD Bioscience (San Francisco, CA), respectively.
Antibodies against HSP27, HSP47, HSP60 and HSP90 were
from Stressgene (San Francisco, CA). The NCode VILO miRNA
cDNA synthesis kit and Lipofectamine (TM2000) were obtained
from Invitrogen (Carlsbad, CA). A771726, gefitinib, imatinib,
amiodarone, L-hydroxyproline, azophloxin and aniline blue were
from WAKO Pure Chemicals (Tokyo, Japan). Xylidine ponceau
was from WALDECK GmbH & Co. (Muenster, Germany), and
Mayer’s hematoxylin, 1% eosin alcohol solution, mounting
medium for histological examination (malinol) and Weigert’s iron
hematoxylin were from MUTO Pure Chemicals (Tokyo, Japan).
Transgenic mice expressing HSP70 were gifts from Drs. CE
Angelidis and GN Pagoulatos (University of Ioannina, Ioannina,
Greece) and were crossed with C57BL/6J wild-type mice 10 times
to generate the mice used in this study [32].
Cell culture
A549 and H1975 cells, and PC9 cells were cultured in DMEM
and RPMI1640 medium, respectively, supplemented with 10%
FBS, 100 U/ml penicillin and 100 mg/ml streptomycin in a
humidified atmosphere of 95% air with 5% CO2 at 37uC.
Real-time RT-PCR analysis
Real-time RT-PCR was performed as previously described [38]
with some modifications. Total RNA was extracted from cells
using an RNeasy kit or mirVana miRNA isolation kit according to
the manufacturer’s protocol. Samples were reverse-transcribed
using a first-strand cDNA synthesis kit or NCode VILO miRNA
cDNA synthesis kit. Synthesized cDNA was used in real-time RT-
PCR experiments (Chromo 4 instrument; Bio-Rad Laboratories)
using iQ SYBR GREEN Supermix, and analyzed with Opticon
Pulmonary Fibrosis by Gefitinib
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analysis of the reaction products and by the inclusion of template-
or reverse transcriptase-free controls. To normalize the amount of
total RNA present in each reaction, actin or RUN44 cDNA was
used as an internal standard. Primers were designed using the
Primer3 website or NCode
TM miRNA database website.
The primers used were (name: forward primer, reverse primer):
hsp27: 5’-ccacccaagtttcctcctc-3’, 5’-gactgggatggtgatctcgt-3’; hsp47:
5’-ccatgttcttcaagccacact-3’, 5’-cgtagtagttgtagaggcctgt-3’; hsp60: 5’-
tttcagatggagtggctgtg-3’, 5’-caatgccttcttcaacagca-3’; hsp70: 5’-aggc-
caacaagatcaccatc-3’, 5’-tcgtcctccgctttgtactt-3’; hsp90: 5’-ggcaga-
ggctgataagaacg-3’, 5’-ctggggatcttccagactga-3’; actin: 5’-ggacttcgag-
caagagatgg-3’, 5’- agcactgtgttggcgtacag-3’; miR-146a: 5’-tgagaact-
gaattccatgggtt-3’; miR-146b-5p: 5’-gtgagaactgaattccataggct-3’; miR-
223*: 5’-gcgtgtatttgacaagctgagtt-3’; miR-561: 5’-cgcaaagtttaa-
gatccttgaagt-3’; miR-449a: 5’-tggcagtgtattgttagctggt-3’; miR-449b:
5’-aggcagtgtattgttagctggc-3’; RUN44: 5’-gagctaattaagaccttcatgttca-3’,
5’-cctggatgatgataagcaaatg-3’. For miRNAs, the universal primer in
the NCode VILO miRNA cDNA synthesis kit was used as the
reverse primer.
We searched for miRNAs that potentially bind to the 3’ UTR of
hsp70, using the TargetScan and Segal Lab websites.
Luciferase assay
DNA fragments of the hsp70 3’ UTR (from 2169 to 2427) were
amplified by PCR and ligated into the SpeI-HindIII site of the
Photinus pyralis luciferase reporter plasmid (pMIR-REPORT) to
generate pMIR/luc/hsp70 3’ UTR. The pGL-3/HSE plasmid was
constructed by inserting HSE just upstream of the luciferase gene.
The pGL-3/hsp70pro plasmid, which was constructed by inserting
the hsp70 promoter into the same region, was generously provided
by Dr. Chang EB (University of Chicago). The luciferase assay was
performed as described previously [38]. Transfections were
carried out using Lipofectamine (TM2000) according to the
manufacturer’s instructions. Cells were used for experiments after
a 24 h recovery period. Transfection efficiency was determined in
parallel plates by transfection of cells with a pEGFP-N1 control
vector. Cells were transfected with 0.5 mg of one of the Photinus
pyralis luciferase reporter plasmids (pMIR/luc/hsp70 3’ UTR,
pGL-3/hsp70pro or pGL-3/HSE) and 0.125 mg of the internal
standard plasmid bearing the Renilla reniformis luciferase reporter
(pRL-SV40). Photinus pyralis luciferase activity in the cell extracts
was measured using the Dual Luciferase Assay System and then
normalized for Renilla reniformis luciferase activity.
Immunoblotting analysis
Whole cell extracts were prepared as described previously [38].
The protein concentration of the samples was determined by the
Bradford method [39]. Samples were applied to polyacrylamide
SDS gels, subjected to electrophoresis, and the resultant proteins
immunoblotted with their respective antibodies.
Pulse-chase and pulse-labelling analyses
Pulse-chase and pulse-labelling analyses were carried out as
described previously [40], with some modifications. Cells were
labelled with [
35S]methionine and [
35S]cysteine in methionine-
and cysteine-free RPMI1640 medium for 15 min. To chase
labelled proteins, cells were washed with fresh complete (with
methionine and cysteine) medium three times and incubated in
complete medium for 4 or 8 h. HSP70 was immunoprecipitated
with its antibody and separated by SDS-polyacrylamide gel
electrophoresis, and visualised by autoradiography (Fuji BAS
2500 imaging analyzer).
Transfection of cells with siRNA or miRNA mimic RNA
fragments
The siRNA for Dicer1 and the miRNA mimic RNA fragments
for miR-146a and miR-146b-5p were purchased from Qiagen.
A549 cells were transfected with these RNAs using HiPerFect
transfection reagents according to the manufacturer’s instructions.
The siRNA (5’-uucuccgaacgugucacgudTdT-3’ and 5’-acgugacac-
guucggagaadTdT-3’) was used as a non-specific siRNA.
Administration of bleomycin, gefitinib and GGA
C57BL/6 mice were maintained under chloral hydrate
anesthesia (500 mg/kg) and given one intratracheal injection of
bleomycin (1 or 2 mg/kg) to induce fibrosis. Gefitinib (200 mg/kg)
was dissolved in 1% methylcellulose and administered orally.
GGA (200 mg/kg) was dissolved in 5% arabic gum and 0.06%
Tween and administered orally.
Histological analysis
Lung tissue samples were fixed in 4% buffered paraformalde-
hyde and embedded in paraffin before being cut into 4 mm-thick
sections.
For histological examination, sections were stained first with
Mayer’s haematoxylin and then with 1% eosin alcohol solution.
Samples were mounted with malinol and inspected with the aid of
an Olympus BX51 microscope.
For Masson’s trichrome staining of collagen, sections were
sequentially treated with solution A (5% (w/v) potassium dichro-
mate and 5% (w/v) trichloroacetic acid), Weigert’s iron hematox-
ylin, solution B (1.25% (w/v) phosphotungstic acid and 1.25% (w/v)
phosphomolybdic acid), 0.75%(w/v) Orange G solution, solution C
(0.12% (w/v) xylidine ponceau, 0.04% (w/v) acid fuchsin and
0.02% (w/v) azophloxin), 2.5% (w/v) phosphotungstic acid, and
finally aniline blue solution. Samples were mounted with malinol
and inspected with the aid of an Olympus BX51 microscope.
Hydroxyproline determination
Hydroxyproline content was determined as previously described
[41]. Briefly, the right lung was removed and homogenized in
0.5 ml of 5% TCA. After centrifugation, pellets were hydrolyzed
in 0.5 ml of 10 N HCl for 16 h at 110uC. Each sample was
incubated for 20 min at room temperature after the addition of
0.5 ml of 1.4% (w/v) chloramine T solution and then incubated at
65uC for 10 min after the addition of 0.5 ml of Ehrlich’s reagent
(1M DMBA, 70% (v/v) isopropanol and 30% (v/v) perchloric
acid). Absorbance was measured at 550 nm and the amount of
hydroxyproline was determined.
Statistical analysis
Two-way analysis of variance (ANOVA), followed by the Tukey
test or the Student’s t-test for unpaired results, was used to evaluate
differences between more than three groups or between two
groups, respectively. Differences were considered to be significant
for values of P,0.05.
Results
Suppression of expression of HSP70 by gefitinib
We first examined the effects of drugs known to induce ILD
clinically (A771726 (an active metabolite of leflunomide), amio-
darone, gefitinib and imatinib) on the expression of HSP70 in
cultured human type II alveolar (A549) cells. As shown in Fig. S1,
a decrease in the level of HSP70 was observed in cells treated with
gefitinib but not in cells treated with other drugs.
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the level of not only HSP70 but also HSP90 in a dose-dependent
manner; however, the decrease was only clearly observed for
HSP70 and not for HSP90, at the concentration of 1 mM. In
contrast, levels of other HSPs (HSP27, HSP47 and HSP60) were
not affected by treatment with gefitinib (Fig. 1A). Erlotinib is
another inhibitor of EGFR used clinically [42] and here we found
that this drug also decreases the levels of HSP70 and HSP90
(Fig. 1B), suggesting that the inhibitory effect of gefitinib on EGFR
is involved in the decrease in the level of HSP.
Real-time RT-PCR analysis revealed that treatment of cells
with gefitinib at 1 mM, a concentration determined to be sufficient
to decrease the level of HSP70 (Fig. 1A), did not affect the hsp70
mRNA level; however, this drug decreased the level at
concentrations higher than 10 mM (Fig. 1C).
Suppression of translation of HSP70 by gefitinib
The cellular level of protein is regulated by various factors, such
as transcription, mRNA stability, translation and protein stability.
With these possibilities in mind, we then examined which of these
factors is affected by gefitinib in relation to HSP70. The results in
Fig. 1C suggest that 1 mM gefitinib does not affect the
transcription and mRNA stability of hsp70.
To confirm this, a luciferase reporter assay was used to examine
the effect of gefitinib on the promoter activity of hsp70. Treatment
of cells with gefitinib did not affect the luciferase activity in cells
carrying a reporter plasmid with an hsp70 promoter or an HSE
inserted upstream of the luciferase gene (Fig. 2A), suggesting that
gefitinib does not affect the promoter activity of hsp70. Further to
this, 1 mM gefitinib did not affect the hsp70 mRNA level in cells
pre-treated with actinomycin D, an inhibitor of transcription
(Fig. 2B), suggesting that treatment of cells with 1 mM gefitinib
does not affect hsp70 mRNA stability. The results in Fig. 1A and B
also suggest that treatment of cells with 10 mM gefitinib affects
hsp70 mRNA stability but not promoter activity.
We then tested whether gefitinib affects the translation and
degradation of HSP70. As shown in Fig. 2C, the decrease in the
level of HSP70 with 1 mM gefitinib was not observed in cells pre-
Figure 1. Suppression of expression of HSPs by gefitinib. A549 cells were incubated with the indicated concentration of gefitinib (A, C) or
erlotinib (B) for 24 h (A, B) or 12 h (C). Whole-cell extracts were analyzed by immunoblotting with an antibody against HSP70, HSP90, HSP27, HSP47,
HSP60 or actin (A, B). Total RNA was extracted and subjected to real-time RT-PCR using a specific primer set for each gene. Values were normalized to
the actin gene, expressed relative to the control sample (C). Values shown are mean 6 S.D. (n=3). **P,0.01.
doi:10.1371/journal.pone.0027296.g001
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Furthermore, a protein pulse-labelling experiment showed that the
synthesis of HSP70 was inhibited in cells pre-treated with gefitinib
(Fig. 2D). These results suggest that 1 mM gefitinib inhibits the
translation of HSP70. On the other hand, the results of the pulse-
chase experiment suggest that treatment of cells with 1 mM
gefitinib does not affect the stability of HSP70; 1 mM gefitinib did
not affect the level of labelled HSP70 after chase periods of 4 h or
8 h (Fig. 2E). The results in Fig. 2E also suggest that treatment of
cells with 10 mM gefitinib stimulates the degradation of HSP70.
3’ UTRs of genes play an important role in translational
regulation, including that by miRNAs. Thus, we examined the
contribution of this region to gefitinib-induced suppression of
expression of HSP70 by a luciferase reporter assay. Treatment of
cells with gefitinib significantly decreased the luciferase activity in
cells carrying the reporter plasmid in which the 3’ UTR of hsp70
was inserted downstream of the luciferase gene (Fig. 3A), suggesting
that 3’ UTR-mediated modulation of HSP70 translation plays an
important role in the gefitinib-induced suppression of HSP70
expression.
The contribution of miRNAs to gefitinib-induced suppression of
HSP70 expression was then tested by use of siRNA for Dicer1, a
protein essential for maturation of miRNAs. As shown in Fig. 3B,
transfection of cells with siRNA for Dicer1 decreased the level of
Dicer1 mRNA, but not that of hsp70, suggesting that the miRNA
system is not involved in the regulation of hsp70 mRNA stability.
The decrease in the level of HSP70 and inhibition of HSP70
protein synthesis in the presence of 1 mM gefitinib were not
observed in cells transfected with siRNA for Dicer1 (Fig. 3C and
D), suggesting that the 1 mM gefitinib-dependent inhibition of
HSP70 translation is mediated by the miRNA system. However,
the 10 mM gefitinib-dependent decrease in the level of HSP70 and
inhibition of protein synthesis of HSP70 were observed even in
cells transfected with siRNA for Dicer1 (Fig. 3C and D).
Next, using a database, we searched for miRNAs with
sequences complementary to the 3’ UTR of hsp70. Six candidate
miRNAs were found (miR-146a, miR-146b-5b, miR-223*, miR-
561, miR-449a and miR-449b). Real-time RT-PCR analysis
revealed that among these miRNAs, the levels of miR-146a and
miR-146b-5b clearly increased after treatment of cells with 1 mM
gefitinib (we used experimental conditions of real-time RT-PCR
under which only fully processed miRNA could be detected)
(Fig. 4A). Furthermore, transfection of cells with siRNA for Dicer1
suppressed this gefitinib-dependent increase in the levels of these
miRNAs (miR-146a, miR-146b-5b) (Fig. 4B) and transfection of
cells with synthesized miR-146a and miR-146b-5b mimic RNA
fragments decreased the level of HSP70 (Fig. 4C and D) but not
that of hsp70 mRNA (Fig. 4E). These results suggest that a
gefitinib-dependent increase in the levels of miR-146a and miR-
146b-5b is involved in gefitinib-dependent inhibition of HSP70
translation.
Involvement of EGFR and JNK inhibition in gefitinib-
dependent suppression of expression of HSP70
As described above, gefitinib inhibits self-phosphorylation of
tyrosine residues in the cytosolic domains of EGFR. Thus, here we
tested whether or not gefitinib suppresses expression of HSP70
through inhibition of the EGFR. To do this we used the cell lines
H1975 and PC9 which are resistant or sensitive, respectively, to
gefitinib-induced inhibition of the self-phosphorylation of EGFR
and the resulting modulation of intracellular signal transduction
due to mutations in the EGFR [43], [44]. As shown in Fig. 5A, the
concentration of gefitinib required for suppression of HSP70
expression was higher and lower in H1975 cells and PC9 cells,
Figure 2. Translational regulation of expression of HSP70 by gefitinib. A549 cells were co-transfected with pRL-SV40 (internal control
plasmid carrying the R. reniformis luciferase gene) and a pGL-3 derivative (pGL-3/hsp70pro or pGL-3/HSE) and cultured for 24 h. Cells were incubated
with the indicated concentration of gefitinib for 24 h and P. pyralis luciferase activity was measured and normalized for R. reniformis luciferase activity.
The 100% value of the P. pyralis luciferase activity is 6.9610
4 or 5.8610
4 units for pGL-3/hsp70pro or pGL-3/HSE, respectively (A). A549 cells were pre-
incubated with 1 mg/ml actinomycin D (ActD) (B) or 20 mg/ml cycloheximide (C) for 1 h and further incubated for 8 h (B) or 24 h (C) with the
indicated concentration of gefitinib (B, C). The mRNA (B) and protein (C) expression was monitored and is expressed as described in the legend of Fig.
1 A549 cells were pulse-labelled for 15 min with [
35S]methionine and [
35S]cysteine (D, E). Before the pulse-labelling, cells were incubated with the
indicated concentration of gefitinib for 8 h (D). Pulse-labelled proteins were chased with excess amounts of Non-radioactively labeled methionine
and cysteine for the indicated period in the presence of the indicated concentration of gefitinib (E). Labelled proteins were extracted,
immunoprecipitated with antibody against HSP70, subjected to SDS-PAGE and autoradiographed (D, E). Values are mean 6 S.D. (n=3). **P,0.01.
doi:10.1371/journal.pone.0027296.g002
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suppresses expression of HSP70 through an inhibitory effect on
the self-phosphorylation of EGFR.
Activation of the EFGR affects various cellular responses
through modulation of intracellular signal transduction, such as
activation of JNK and ERK [45], [46]. To test whether inhibition
of JNK or ERK is involved in gefitinib-dependent suppression of
HSP70 expression, we examined the effect of inhibitors of JNK
and ERK, SP600125 and U0126, respectively, on the expression
of HSP70. Treatment of cells with SP600125 (Fig. 5B) but not
U0126 (data not shown) decreased the level of HSP70, suggesting
that the inhibition of JNK is involved in the gefitinib-dependent
suppression of HSP70 expression.
Effect of gefitinib on bleomycin-induced pulmonary
fibrosis
As described in the Introduction, we recently reported that
expression of HSP70 protects against bleomycin-induced pulmo-
nary fibrosis [35]. Therefore, the in vitro results outlined above
imply that gefitinib exacerbates bleomycin-induced pulmonary
fibrosis through suppression of HSP70 expression. To test this, we
examined the effect of oral daily administration of gefitinib on the
expression of HSP70 in the lungs. As shown in Fig. S2, this
administration decreases the level of HSP70. The decrease became
apparent at day 3 and was also observed at day 6 (Fig. S2).
Therefore, to examine the effect of administration of gefitinib on
bleomycin-induced pulmonary fibrosis, mice were orally admin-
istered gefitinib once per day for three days before receiving a
single intratracheal administration of bleomycin; the administra-
tion of gefitinib was then continued, once every two days, for the
following 14 days.
Histopathological analysis of pulmonary tissue using hematox-
ylin and eosin (H & E) staining revealed that the simultaneous oral
administration of gefitinib (200 mg/kg) and intratracheal admin-
istration of bleomycin (1 mg/kg) produced severe pulmonary
damage (thickened and edematous alveolar walls and interstitium,
and infiltration of leucocytes) (Fig. 6A). Administration of either
gefitinib or bleomycin alone did not cause such clear-cut
pulmonary damage (Fig. 6A). Masson’s trichrome staining of
collagen revealed that administration of bleomycin caused slight
collagen deposition, an effect that was greatly exacerbated by
simultaneous administration of gefitinib (Fig. 6B). The pulmonary
hydroxyproline level (an indicator of collagen levels) was increased
by administration of bleomycin alone, and this effect was further
Figure 3. Contribution of miRNA to gefitinib-dependent suppression of expression of HSP70. A549 cells were co-transfected with pRL-
SV40 and pMIR/luc/hsp70 3’ UTR and cultured for 24 h. Cells were incubated with the indicated concentration of gefitinib for 24 h and luciferase
reporter assay was done as described in the legend of Fig. 2. The 100% value of the P. pyralis luciferase activity is 1.2610
5 units (A). A549 cells were
transfected with siRNA for Dicer1 (siDicer1) or non-specific siRNA (ns) (B-D). After 24 h, cells were incubated with the indicated concentration of
gefitinib for 12 h (B), 24 h (C) or 8 h (D). The mRNA (B) and protein (C) expression was monitored and is expressed as described in the legend of Fig. 1.
Pulse-labelling experiments were performed as described in the legend of Fig. 2 (D). Values shown are mean 6 S.D. (n=3). **P,0.01; n.s., not
significant.
doi:10.1371/journal.pone.0027296.g003
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Under our experimental conditions, administration of gefitinib
alone did not cause collagen deposition nor increase the level of
pulmonary hydroxyproline (Fig. 6B and E).
We also performed similar experiments in transgenic mice
expressing HSP70. Since these mice are resistant to bleomycin, we
used a higher dose (2 mg/kg) of bleomycin than in the previously
described experiments. As shown in Fig. 6C, D and F, the
gefitinib-dependent enhancement of bleomycin-induced pulmo-
nary damage, collagen deposition and increase in pulmonary
hydroxyproline level were not clearly observed in the transgenic
mice, suggesting that gefitinib exacerbates bleomycin-induced
pulmonary fibrosis through the suppression of HSP70 expression.
To test this idea, we examined the effect of the administration of
gefitinib and/or bleomycin on pulmonary expression of HSP70 in
wild-type mice and transgenic mice expressing HSP70. To begin
with, we confirmed the overexpression of HSP70 in the lungs of
transgenic mice in both the presence and absence of gefitinib
administration (Fig. 6G). As shown in Fig. 6H and I, in wild-type
mice, administration of gefitinib decreased the pulmonary level of
HSP70 in both the presence and absence of simultaneous
bleomycin administration. Administration of bleomycin alone also
decreased the pulmonary level of HSP70 (Fig. 6H and I). In
contrast, such a gefitinib-dependent decrease in the pulmonary
level of HSP70 was not observed clearly in transgenic mice
expressing HSP70 in both the presence or absence of simultaneous
administration of bleomycin (Fig. 6J). We also found that using a
lower dose of gefitinib (100 mg/kg) neither exacerbated bleomy-
cin-induced pulmonary fibrosis nor suppressed pulmonary expres-
sion of HSP70 (Fig. S3). These results suggest that administration
of gefitinib exacerbates bleomycin-induced pulmonary fibrosis
through suppression of HSP70 expression.
Figure 4. Identification of miRNAs involved in gefitinib-dependent suppression of expression of HSP70. A549 cells were incubated
with the indicated concentration of gefitinib for 3 h (A). A549 cells were transfected with siRNA for Dicer1 (siDicer1) or non-specific siRNA (ns) and
after 24 h were incubated with the indicated concentration of gefitinib for 3 h (B). A549 cells were transfected with the indicated amount ( mg/well)
of miRNA mimic RNA fragments for 24 h (C, E). The RNA (A, B, E) and protein (C) expression was monitored and expressed as described in the legend
of Fig. 1. The RUN44 non-coding RNA was used for normalization (A, B, E). The intensities of the HSP70 bands were determined and are expressed
relative to the control (one of the gels is shown in C) (D). Values shown are mean 6 S.D. (n=3). **P,0.01; *P,0.05; n.s., not significant.
doi:10.1371/journal.pone.0027296.g004
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co-administration of GGA. As shown in Fig. 7A-C, co-adminis-
tration of GGA clearly suppressed the gefitinib-dependent
enhancement of bleomycin-induced pulmonary tissue damage,
collagen deposition and increases in the pulmonary hydroxypro-
line level in wild-type mice. We also examined the effect of GGA
on the expression of HSP70 in the lung. As shown in Fig. 7D and
E, co-administration of GGA recovered the gefitinib-suppressed
expression of HSP70 in the lung, suggesting that GGA suppresses
the gefitinib-dependent exacerbation of bleomycin-induced pul-
monary fibrosis by inducing the recovery of HSP70 expression.
Discussion
Because the molecular mechanism governing drug-induced ILD
(interstitial pneumonia associated with pulmonary fibrosis) is
unknown, a suitable animal model is not available at present.
Consequently, neither a clinical protocol for the treatment of drug-
induced ILD nor an assay system to eliminate candidate drugs
with the potential to cause this type of side effect has been
established. We recently reported that A771726, an active
metabolite of leflunomide, induced EMT of lung epithelial cells
both in vitro and in vivo, and that administration of leflunomide
exacerbated bleomycin-induced pulmonary fibrosis, suggesting
that the leflunomide-dependent exacerbation of bleomycin-
induced pulmonary fibrosis is mediated by the stimulation of
EMT of lung epithelial cells. We proposed that examination of the
EMT-inducing ability of candidate drugs is useful for screening to
eliminate those with the potential side effect of inducing
pulmonary fibrosis. We also found that leflunomide-dependent
exacerbation of bleomycin-induced pulmonary fibrosis is amelio-
rated by the simultaneous intratracheal administration of uridine,
which suppresses the A771726-dependent induction of EMT in
vitro, and propose that this administration is beneficial for the
treatment of leflunomide-induced pulmonary fibrosis in humans.
In the present study, we followed a similar strategy, focusing on the
expression of HSP70, because we had recently reported that
expression of HSP70 protects against bleomycin-induced pulmo-
nary fibrosis through cytoprotective and anti-inflammatory effects
and, by inhibiting the production of TGF-b1 and TGF-b1-
dependent EMT of lung epithelial cells [35].
We have found that gefitinib suppresses the expression of
HSP70 in vitro. The concentration of gefitinib used (1 mM) is
similar to that obtained in plasma when administered at
therapeutic levels (about 1-2 mM) [47]. Thus, we considered that
the suppression of HSP70 expression by gefitinib is clinically
relevant and investigated the molecular mechanism underlying
this effect. We concluded that treatment of cells with gefitinib
(1 mM) decreases the level of HSP70 through inhibition of
translation based on observations that (i) the gefitinib-dependent
decrease in the level of HSP70 was suppressed by an inhibitor of
translation, (ii) the translation of HSP70, measured by pulse-
labelling experiments, was inhibited by treatment of cells with
gefitinib, and (iii) hsp70 promoter activity, the level and stability of
hsp70 mRNA and the stability of HSP70 were all unaffected by
treatment of cells with gefitinib. Furthermore, we suggested that
two miRNAs (miR-146a and miR-146b-5p) are involved in this
gefitinib-dependent suppression of HSP70 translation; this was
based on our observations that (i) the introduction of the 3’ UTR
of hsp70 into a luciferase reporter plasmid caused a gefitinib-
dependent decrease in luciferase activity, (ii) the gefitinib-
dependent suppression of HSP70 translation was not observed in
cells transfected with siRNA for Dicer1, and (iii) gefitinib increased
the levels of miR-146a and miR-146b-5p, both of which have the
ability to decrease the level of HSP70. Since for various cancer
cells and tissues, down-regulation of expression of these miRNAs
and up-regulation of HSP70 and the contribution of these to
cancer progression have been reported [48], [49], [50], the results
Figure 5. Involvement of inhibition of EGFR and JNK in gefitinib-dependent suppression of expression of HSP70. A549 (A-C) and
H1975 and PC9 (A) cells were incubated with the indicated concentration of gefitinib (A, B) or SP600125 (B) for 24 h. Protein expression was
monitored and is expressed as described in the legend of Fig. 1.
doi:10.1371/journal.pone.0027296.g005
Pulmonary Fibrosis by Gefitinib
PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e27296Pulmonary Fibrosis by Gefitinib
PLoS ONE | www.plosone.org 9 November 2011 | Volume 6 | Issue 11 | e27296of this study suggest the latter up-regulation is caused by the
former down-regulation.
A decrease in the level of HSP70 was also observed in cells
treated with 10 mM gefitinib; however, the mechanism governing
this decrease seems to be different from that seen with 1 mM
gefitinib, because treatment of cells with 10 mM gefitinib caused a
decrease in the level of hsp70 mRNA and in the stability of both
hsp70 mRNA and HSP70. We consider that this high con-
Figure 6. Effect of gefitinib on bleomycin-induced pulmonary fibrosis and pulmonary expression of HSP70. Wild-type mice (A, B, E, G,
H) and transgenic mice expressing HSP70 (C, D, F, G, J) were orally administered gefitinib (200 mg/kg) or vehicle once per day for 3 days (from day 0
to day 2), then treated once only with or without 1 mg/kg (for wild-type mice) or 2 mg/kg (for the transgenic mice) bleomycin (BLM) (day 3). Mice
were then orally administered gefitinib (200 mg/kg) or vehicle once per 2 days for 14 days (from day 3 to day 17). Sections of pulmonary tissue were
prepared at day 17 and subjected to histological examination (H & E staining (A, C) or Masson’s trichrome staining (B, D)) (scale bar, 50 mm) (A-D).
Pulmonary hydroxyproline levels at day 17 were determined (E, F). Total protein was extracted from pulmonary tissues at day 17 and analyzed by
immunoblotting with an antibody against HSP70 or actin (G, H, J). The intensities of the HSP70 bands were determined (one of the gels is shown in H)
and are expressed relative to the control (I). Values are mean 6 S.E.M. *P,0.05; **P,0.01; n.s., not significant.
doi:10.1371/journal.pone.0027296.g006
Figure 7. Effect of GGA on gefitinib-dependent exacerbation of pulmonary fibrosis and pulmonary expression of HSP70. Wild-type
mice were orally administered gefitinib (200 mg/kg) and/or GGA (200 mg/kg) once per day for 3 days (from day 0 to day 2), then treated once only
with 1 mg/kg bleomycin (BLM) (day 3). Mice were then orally administered gefitinib (200 mg/kg) and/or GGA (200 mg/kg) once per 2 days for 14
days (from day 3 to day 17). Sections of pulmonary tissue were prepared at day 17 and subjected to histological examination (H & E staining (A) or
Masson’s trichrome staining (B)) (scale bar, 50 mm). The pulmonary hydroxyproline levels were determined at day 17 (C). Total protein was extracted
from pulmonary tissues at day 17 and analyzed and expressed as described in the legend of Fig. 6 (D, E). Values are mean 6 S.E.M. **P,0.01; *P,0.05.
doi:10.1371/journal.pone.0027296.g007
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reactions.
After binding EGF, the EGFR is self-phosphorylated and
transduces the signal via various mechanisms, including the
activation of JNK. Here, we have found that mutations in the
EGFR that alter the concentration of gefitinib required for
inhibition of EGFR self-phosphorylation affect the gefitinib-
dependent decrease in the level of HSP70. Furthermore, an
inhibitor of JNK caused a decrease in the level of HSP70. These
results suggest that inhibition of EGFR self-phosphorylation and
the resulting inhibition of JNK are involved in the gefitinib-
dependent decrease in the level of HSP70. However, the manner
by which inhibition of JNK suppresses translation of HSP70
remains unclear.
Administration of gefitinib alone did not produce pulmonary
fibrosis under our experimental conditions. As one of the risk
factors for gefitinib-induced ILD is pre-existing pulmonary
fibrosis, we hypothesized that gefitinib stimulates pulmonary
fibrosis in the presence of other fibrosis-inducing stimuli. In fact,
we found that administration of gefitinib stimulates bleomycin-
induced pulmonary fibrosis. Interestingly, this gefitinib-dependent
stimulation was not observed so clearly in transgenic mice
expressing HSP70, suggesting that expression of HSP70 is
involved in the gefitinib-induced exacerbation of bleomycin-
induced pulmonary fibrosis. We found that administration of
gefitinib suppressed the pulmonary expression of HSP70 and that
this suppression was not observed in the transgenic mice
expressing HSP70. Taken together, our findings suggest that
gefitinib exacerbates bleomycin-induced pulmonary fibrosis
through the suppression of HSP70 expression. This finding is an
important step towards elucidating the molecular mechanism of
drug-induced ILD, as well as the mechanism governing the ethnic
differences in susceptibility to ILD induced by the drug. It is
possible that the susceptible phenotype of Japanese patients is due
to a specific polymorphism in the hsp70 and hsf1 genes and in other
genes related to HSP70. Also, examination of the effect of
candidate drugs on the expression of HSP70 in vitro could be used
for screening to eliminate those drugs with the potential to induce
ILD. Furthermore, exacerbation of bleomycin-induced pulmonary
fibrosis was observed with leflunomide [7] and gefitinib (this
study), suggesting this model can be used as an animal model of
drug-induced pulmonary fibrosis and for screening to eliminate
candidate drugs with the potential to induce ILD.
As described above, it was recently reported that administration
of GGA ameliorates bleomycin-induced pulmonary fibrosis [51], a
result that we confirmed in a previous paper [35], In this study, we
found that administration of GGA suppresses the gefitinib-
dependent exacerbation of bleomycin-induced pulmonary fibrosis.
We consider that this suppression is due to the recovery of HSP70
expression in the lung. As described in the Introduction, a
treatment for drug-induced ILD has not been established. We
believe that GGA could be beneficial for the treatment of gefitinib-
induced ILD, given that the safety of GGA has already been
shown clinically.
Supporting Information
Figure S1 Effects of drugs known to induce ILD
clinically on expression of HSP70. A549 cells were incubated
with the indicated concentration of A771726, amiodarone (AMD),
gefitinib or imatinib for 24 h. Whole cell extracts were analyzed by
immunoblotting with an antibody against HSP70 or b-actin.
(TIFF)
Figure S2 Time course profile for gefitinib-dependent
suppression of expression of HSP70 in vivo. Mice were
orally administered gefitinib (200 mg/kg) or vehicle once per day
for the indicated periods. Total protein was extracted from
pulmonary tissues and protein expression was monitored by
immunoblotting with an antibody against HSP70 or b-actin.
(TIFF)
Figure S3 Effect of low dose of gefitinib on bleomycin-
induced pulmonary fibrosis and pulmonary expression
of HSP70. The effect of a low dose of gefitinib (100 mg/kg) on
the expression of HSP70 in the lung (A) and pulmonary
hydroxyproline levels (B) were monitored as described in the
legend of Fig. 6. Values are mean 6 S.E.M.
(TIFF)
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